vs
亚玛芬体育（AS）与爱德华生命科学（EW）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是亚玛芬体育的1.6倍（$1.6B vs $1.1B），爱德华生命科学净利率更高（23.1% vs 1.8%，领先21.3%）
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
AS vs EW — 直观对比
营收规模更大
EW
是对方的1.6倍
$1.1B
净利率更高
EW
高出21.3%
1.8%
损益表 — Q1 FY2024 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.6B |
| 净利润 | $19.0M | $380.7M |
| 毛利率 | 52.8% | 78.0% |
| 营业利润率 | 12.4% | 1.8% |
| 净利率 | 1.8% | 23.1% |
| 营收同比 | — | 16.7% |
| 净利润同比 | — | 6.8% |
| 每股收益（稀释后） | $0.05 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASEW
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
净利润ASEW
| Q1 26 | — | $380.7M | ||
| Q4 25 | — | $91.2M | ||
| Q3 25 | — | $291.1M | ||
| Q2 25 | — | $333.2M | ||
| Q1 25 | — | $358.0M | ||
| Q4 24 | — | $385.6M | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $366.3M |
毛利率ASEW
| Q1 26 | — | 78.0% | ||
| Q4 25 | — | 78.1% | ||
| Q3 25 | — | 77.8% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 79.9% |
营业利润率ASEW
| Q1 26 | — | 1.8% | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | 19.8% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 27.9% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 25.9% | ||
| Q2 24 | — | 26.8% |
净利率ASEW
| Q1 26 | — | 23.1% | ||
| Q4 25 | — | 5.8% | ||
| Q3 25 | — | 18.7% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 226.7% | ||
| Q2 24 | — | 26.7% |
每股收益（稀释后）ASEW
| Q1 26 | — | $0.66 | ||
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.50 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $0.61 | ||
| Q4 24 | — | $0.65 | ||
| Q3 24 | — | $5.13 | ||
| Q2 24 | — | $0.61 |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.3M | — |
| 自由现金流经营现金流 - 资本支出 | $92.2M | — |
| 自由现金流率自由现金流/营收 | 8.8% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 6.02× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASEW
| Q1 26 | — | — | ||
| Q4 25 | — | $450.9M | ||
| Q3 25 | — | $573.7M | ||
| Q2 25 | — | $290.2M | ||
| Q1 25 | — | $280.4M | ||
| Q4 24 | — | $-127.5M | ||
| Q3 24 | — | $351.8M | ||
| Q2 24 | — | $371.5M |
自由现金流ASEW
| Q1 26 | — | — | ||
| Q4 25 | — | $353.5M | ||
| Q3 25 | — | $516.2M | ||
| Q2 25 | — | $240.9M | ||
| Q1 25 | — | $224.4M | ||
| Q4 24 | — | $-177.3M | ||
| Q3 24 | — | $299.9M | ||
| Q2 24 | — | $286.1M |
自由现金流率ASEW
| Q1 26 | — | — | ||
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 33.2% | ||
| Q2 25 | — | 15.7% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | -12.8% | ||
| Q3 24 | — | 22.1% | ||
| Q2 24 | — | 20.9% |
资本支出强度ASEW
| Q1 26 | — | — | ||
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 6.2% |
现金转化率ASEW
| Q1 26 | — | — | ||
| Q4 25 | — | 4.94× | ||
| Q3 25 | — | 1.97× | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | -0.33× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
EW
暂无分部数据
